Austin Perlmutter
Austin Perlmutter is a researcher and science communicator working in the fields of brain health, nutrition, and wellness. His published research investigates the relationship between the gut and the mind, including the effects of psychedelic healing practices on the microbiome. His work also covers the impact of polyphenol supplementation on immune aging markers and the immunological connections between COVID-19 and depression.
36 claims checked on air: 3 context 1 contradicted 1 overstated 26 supported 5 unverified
What they said on air
Cardiovascular disease is the leading cause of death.
"and dying of what was then and is still the number one cause of death, which is cardiovascular disease." (said at 0:02:35)
Extensive global epidemiological data, including findings from the Global Burden of Disease (GBD) Study and the World Health Organization, confirm that cardiovascular disease (principally ischemic heart disease and stroke) remains the leading cause of mortality worldwide. In 2019, cardiovascular disease accounted for approximately 18.6 million deaths globally.
Muscles are the primary source of heat in the human body.
"Your muscles are attached to bones by tendons. They're the primary source of your body's heat, and you have three major types of muscles." (said at 0:04:39)
The claim is roughly accurate but requires physiological context. Under resting, thermoneutral conditions (basal metabolic rate), internal organs (such as the liver, brain, heart, and kidneys) produce the majority (approximately 60–70%) of core body heat, while resting skeletal muscle contributes roughly 20–30%. However, during physical activity, exercise, cold exposure, or shivering thermogenesis, skeletal muscle becomes the predominant source of heat production in the human body, generating up to 80–90% of total metabolic heat.
The human body contains over 600 individual muscles.
"your body has over 600 individual muscles." (said at 0:04:58)
Standard human anatomical literature consistently recognizes that the human muscular system contains over 600 distinct skeletal muscles (typically estimated between 600 and 650 to over 800 depending on whether bilateral pairs and muscle subdivisions are counted separately). Scientific and medical reviews commonly reference approximately 650 named skeletal muscles throughout the body.
Skeletal muscle can constitute up to 40% of body weight and contains up to 75% of total body protein.
"skeletal muscle can be up to 40% of a person's body weight, which really makes it the largest tissue, and it contains up to 75% of the protein in your body." (said at 0:06:12)
No published record matching the claim that skeletal muscle constitutes up to 40% of body weight and contains up to 75% of total body protein was located; this does not prove the claim false.
By around age 80, individuals can lose up to half of their skeletal muscle mass, at a loss rate of up to 1% per year.
"As we basically go through the years and get to around our 80s, we can lose up to half of the skeletal muscle in our body, and the rate can be as much as 1% per year." (said at 0:07:07)
Published quantitative reviews and literature on sarcopenia confirm that skeletal muscle mass declines with age at a rate of approximately 0.5% to 1.0% per year in older adulthood, with longitudinal studies in older populations (aged 75+) reporting muscle mass loss rates reaching up to 0.80–0.98% per year in men. Over the decades from young adulthood into an individual's 80s, this rate of loss accumulates to a substantial overall reduction in total skeletal muscle mass (up to roughly 30–50%).
- supports: Nutrient-rich meat proteins in offsetting age-related muscle loss. (Meat science 2012) · cited 126x in the literature
"Sarcopenia, refers to the loss of muscle mass, and associated muscle weakness, which occurs in aging and is thought to proceed at a rate of approximately 1% loss per year." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and s… (Frontiers in physiology 2012) · cited 1379x in the literature
"Longitudinal studies show that in people aged 75 years, muscle mass is lost at a rate of 0.64-0.70% per year in women and 0.80-00.98% per year in men." (abstract, results, passage verified)
pubmedfull study (doi)
A 2024 meta-analysis found a 56% increased risk of mild cognitive decline and an almost 300% increased risk for Alzheimer's dementia in people with the highest levels of sarcopenia.
"So one recent meta-analysis just published in 2024 found that there was a 56% increased risk of having mild cognitive decline and almost a 300% increased risk for Alzheimer's dementia in people with the highest levels of sarcopenia." (said at 0:07:52)
A 2024 systematic review and meta-analysis published in the Journal of Cachexia, Sarcopenia and Muscle evaluated the relationship between sarcopenia and neurocognitive disorders. It found that sarcopenia was significantly associated with mild cognitive impairment (pooled odds ratio [OR] = 1.58, 95% CI 1.42–1.76) and Alzheimer's disease (pooled OR = 2.97, 95% CI 2.15–4.08). The certainty is low because the pooled evidence consists almost entirely of observational (predominantly cross-sectional) studies.
A review found approximately a 60% increased risk of depression in individuals with the least muscle mass.
"An additional review found that there was up to a 60-ish percent risk for having depression in people who had the least muscle mass, meaning the most sarcopenic." (said at 0:08:12)
A systematic review and meta-analysis of observational studies examining the relationship between sarcopenia (loss of muscle mass and function) and depression reported a crude odds ratio of 1.640 (95% CI: 1.247–2.155), representing approximately a 64% increase in the unadjusted odds of depression among sarcopenic individuals compared to non-sarcopenic controls. After adjusting for confounding factors such as age, sex, cognitive performance, and physical activity, the association remained statistically significant with an adjusted odds ratio of 1.821.
Lactate serves as a backup energy substrate for neurons in the brain.
"Well, actually, lactate is a backup fuel for your neurons, and actually lactate can activate signaling cascades in the brain that might be quite healthy." (said at 0:19:20)
Extensive neuroenergetic research confirms that lactate acts both as a supplemental or alternative oxidative energy substrate for neurons (shuttled from astrocytes or systemic circulation) and as a signaling molecule. Published reviews establish that neuronal uptake of lactate supports basal and activity-dependent ATP production and that lactate triggers intracellular signaling cascades involved in synaptic plasticity, gene expression, memory consolidation, and neuroprotection.
- supports: Lactate: A Novel Signaling Molecule in Synaptic Plasticity and Drug Addiction. (BioEssays : news and reviews in molecular, cellular and developmental biology 2019) · cited 38x in the literature
"L-Lactate is emerging as a crucial regulatory nexus for energy metabolism in the brain and signaling transduction in synaptic plasticity, memory processes, and drug addiction instead of being merely a waste by-product of anaerobic glycolysis." (abstract, passage verified)
pubmedfull study (doi) - supports: Lactate as a determinant of neuronal excitability, neuroenergetics and beyond. (Neurobiology of disease 2023) · cited 47x in the literature
"Over the last decades, lactate has emerged as important energy substrate for the brain fueling of neurons. A growing body of evidence now indicates that it is also a signaling molecule modulating neuronal excitability and activity as well as brain functions." (abstract, passage verified)
pubmedfull study (doi) - supports: Brain energy homeostasis: the evolution of the astrocyte-neuron lactate shuttle hypothesis… (The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 2025) · cited 52x in the literature
"The astrocyte-neuron lactate shuttle (ANLS) hypothesis has emerged as a fundamental framework explaining the metabolic cooperation between astrocytes and neurons, whereby astrocyte-derived lactate serves as a crucial energy substrate for neurons. This review synthesizes current understanding of brain energy metabolism, focusing on the dual roles of lactate as both an energy substrate and a signaling molecule." (abstract, passage verified)
pubmedfull study (doi)
Interleukin-6 is a strong biomarker and predictor for the development of depression and dementia.
"Now, interleukin-6 is one of the best predictors of conditions like depression and dementia. It is one of the most prototypical inflammatory molecules." (said at 0:20:29)
Interleukin-6 (IL-6) is a well-established pro-inflammatory cytokine associated with neuroinflammation, but describing it as 'one of the best predictors' or a 'strong biomarker' for the onset of depression and dementia overstates its predictive power. Systematic reviews and meta-analyses of prospective longitudinal studies show that while elevated IL-6 levels are statistically significantly associated with future depressive symptoms and cognitive decline, the effect sizes are modest (e.g., correlation coefficients r < 0.10 for depression; odds ratios around 1.34 for cognitive decline). IL-6 alone possesses limited individual diagnostic or predictive utility compared to established risk factors and disease-specific biomarkers (such as APOE ε4 status, amyloid-beta, and tau for Alzheimer's disease).
- partial: CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. (Journal of affective disorders 2013) · cited 969x in the literature
"Raised inflammatory markers have a small but significant association with the subsequent development of depressive symptoms. This is a robust effect which remains significant after adjustment for age and a wide range of factors associated with risk for depression." (abstract, conclusions, passage verified)
pubmedfull study (doi) - partial: The longitudinal associations of inflammatory biomarkers and depression revisited: systema… (Molecular psychiatry 2021) · cited 358x in the literature
"Small, prospective associations of depression and inflammatory biomarkers are observed in both directions, particularly for IL-6; however, the strength and importance of this relationship is likely obscured by the heterogeneity in depression and profound study/methodological differences." (abstract, results, passage verified)
pubmedfull study (doi) - partial: Association of inflammation and cognition in the elderly: A systematic review and meta-ana… (Frontiers in aging neuroscience 2023) · cited 108x in the literature
"The data from longitudinal studies suggested that levels of IL-6 significantly increased the risk of cognitive decline [OR = 1.34, 95% CI (1.13, 1.56)]. However, intermediate levels of IL-6 had no significant effect on the final clinical endpoint [OR = 1.06, 95% CI (0.8, 1.32)]." (abstract, results, passage verified)
pubmedfull study (doi)
Between 87% and 93% of Americans have metabolic dysfunction.
"I would say the latest numbers are between 87% and 93% of Americans have some element of metabolic dysfunction" (said at 0:23:20)
Nationally representative analyses of the National Health and Nutrition Examination Survey (NHANES) support the stated range. A 2019 study (Araújo et al.) examining NHANES 2009–2016 data found that only 12.2% of American adults had optimal levels across five key cardiometabolic biomarkers (waist circumference, fasting glucose/HbA1c, blood pressure, triglycerides, and HDL cholesterol without medication), leaving approximately 87.8% with at least one suboptimal marker. A subsequent 2022 analysis (O'Hearn et al.) evaluated NHANES data through 2018 and reported that optimal cardiometabolic health declined to just 6.8% of U.S. adults in 2017–2018, meaning 93.2% had intermediate or poor levels in at least one cardiometabolic parameter.
Weaker grip strength is correlated with higher risks of dementia, depression, and anxiety across large populations.
"and you use surrogates for muscle strength, for example grip strength, which is an interesting tool, having a weaker grip strength is correlated with a higher risk for dementia and a higher risk for depression as well as anxiety." (said at 0:28:40)
Large-scale prospective cohort studies and meta-analyses support the statement. A comprehensive systematic review and meta-analysis of cohort studies (PMID: 41667153) found that lower handgrip strength is significantly associated with higher risks of incident dementia (OR 0.62 for highest vs. lowest grip strength), depression (OR 0.70), and anxiety (OR 0.79). Furthermore, large population-based analyses such as the UK Biobank have confirmed lower handgrip strength as an independent predictor for both dementia and mental health outcomes.
- supports: Clinical importance of simple muscular fitness tests to predict long-term health condition… (British journal of sports medicine 2026) · cited 7x in the literature
"Adults with the highest (vs lowest) handgrip strength levels had a lower risk of multiple long-term health conditions (all p<0.05), including cardiovascular diseases (OR=0.73; 95% CI 0.67 to 0.80), type 2 diabetes mellitus (OR=0.79; 95% CI 0.68 to 0.91), musculoskeletal impairment (OR=0.65; 95% CI 0.56 to 0.76), disability (OR=0.57; 95% CI 0.47 to 0.70), anxiety (OR=0.79; 95% CI 0.63 to 0.99), depression (OR=0.70; 95% CI 0.63 to 0.78), cognitive decline (OR=0.57; 95% CI 0.44 to 0.75), dementia (OR=0.62; 95% CI 0.53 to 0.73) and Parkinson's disease (OR=0.53; 95% CI 0.31 to 0.91)." (abstract, results, passage verified)
pubmedfull study (doi)
Walking 10,000 steps per day correlates with a 50% lower risk of developing dementia over a seven-year period.
"And there's a study that just came out not long ago showing 10,000 steps a day correlated with a 50% lower risk of developing dementia over a seven-year period" (said at 0:29:16)
A 2022 prospective cohort study of 78,430 UK Biobank participants (aged 40–79 years) followed for a median of 6.9 years evaluated the association between accelerometer-measured daily steps and incident dementia. The optimal dose for risk reduction was observed at 9,826 steps per day (hazard ratio 0.49; 95% CI, 0.39–0.62), corresponding to an estimated 51% reduction in the risk of developing dementia compared with lower baseline activity levels.
A meta-analysis comparing HIIT, conventional aerobics, stretching, and resistance training found resistance training to be the most potent intervention for raising brain-derived neurotrophic factor (BDNF) levels.
"And there's another study, it was a meta-analysis where they looked at all the different forms of exercise. So high-intensity interval training, or HIIT, they looked at conventional aerobic, they looked at stretching, and what they found is that resistance training was the most potent intervention when it came to elevating levels of brain-derived neurotrophic factor." (said at 0:29:34)
A 2022 Bayesian network meta-analysis of 39 randomized controlled trials (2,031 participants) evaluating different exercise modalities on brain-derived neurotrophic factor (BDNF) levels found that resistance training (RT) had the largest effect, ranking higher than high-intensity interval training (HIIT), combined training, and aerobic training (ranking: RT > HIIT > combined training > aerobic+resistance > aerobic training > control).
The majority of BDNF required for neuroplasticity is synthesized locally within the brain rather than peripherally.
"it seems like the majority of the BDNF that's important for neuroplasticity is actually produced locally in the brain, which throws off this whole idea that it's peripheral levels that matter." (said at 0:30:25)
No published record matching the claim that the majority of BDNF required for neuroplasticity is synthesized locally within the brain rather than peripherally was located; this does not prove the claim false.
Brain-derived neurotrophic factor (BDNF) levels decrease in depression and Alzheimer's disease, and increase with exercise.
"Levels of BDNF go down in depression, go down in Alzheimer's disease, go up in exercise." (said at 0:30:45)
Extensive meta-analytic evidence confirms all three assertions in the claim:
1. **Depression**: Meta-analyses demonstrate that circulating (serum and plasma) brain-derived neurotrophic factor (BDNF) levels are significantly decreased in patients with acute major depressive disorder compared to healthy controls, and typically normalize following successful antidepressant treatment.
2. **Alzheimer's disease**: Systematic reviews and meta-analyses consistently show that BDNF concentrations in peripheral blood, cerebrospinal fluid (CSF), and post-mortem brain tissue (hippocampus and neocortex) are significantly reduced in patients with Alzheimer's disease compared to cognitively healthy controls.
3. **Exercise**: Systematic reviews and meta-analyses of randomized controlled trials and experimental interventions show that both acute bouts of exercise and regular/chronic physical training (aerobic, resistance, and combined modalities) significantly increase circulating BDNF levels across healthy adults and clinical populations.
- supports: BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitativ… (Journal of affective disorders 2015) · cited 491x in the literature
"Serum and plasma BDNF were decreased in acute MDD and BD, and did not differ in euthymia in comparison with control subjects." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Postmortem Brain, Cerebrospinal Fluid, and Blood Neurotrophic Factor Levels in Alzheimer's… (Journal of molecular neuroscience : MN 2018) · cited 78x in the literature
"Random effects meta-analysis demonstrated that peripheral blood BDNF levels were significantly decreased in AD patients compared with controls... In CSF, random effects meta-analysis showed significantly deceased BDNF and increased NGF levels in patients with AD" (abstract, results)
pubmedfull study (doi) - supports: Decreased Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Patients with Alzheimer… (International journal of molecular sciences 2019) · cited 419x in the literature
"Fifteen studies were included for the comparison between AD and healthy control (HC) ( n = 2067). Serum BDNF levels were significantly lower in patients with AD (SMD: -0.282; 95% confidence interval [CI]: -0.535 to -0.028; significant heterogeneity: I² = 83.962)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Effects of Regular Exercise on Peripheral Brain-Derived Neurotrophic Factor in Neurologica… (Brain sciences 2025) · cited 2x in the literature
"Nineteen RCTs, including 850 participants, were analyzed. According to low-quality evidence, exercise significantly increased peripheral BDNF (SMD = 1.03, 95% CI: [0.56-1.49, p < 0.0001)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Acute cardiovascular exercise and circulating neurotrophic factors in humans: A systematic… (Brain research 2026) · cited 1x in the literature
"The meta-analysis confirmed a moderate, statistically significant increase in circulating BDNF (pooled Hedges' g = 0.48, 95 % CI [0.29, 0.68], p < 0.001), with directionally larger effects following higher-intensity exercise and in younger adults." (abstract, results, passage verified)
pubmedfull study (doi)
SSRIs and SNRIs fail to work in about one-third of people with depression even after multiple medications are tried.
"What we've seen is not only does this drug not work in about a third of people, even after multiple kind of agents are used in the SSRI/SNRI family" (said at 0:37:01)
No published record matching the claim that SSRIs and SNRIs fail to work in about one-third of people with depression even after multiple medications are tried was located; this does not prove the claim false.
SSRIs have a side effect rate of approximately 50% and a withdrawal/discontinuation effect rate of approximately 50%.
"the side effect rates are 50%, and the withdrawal effects are 50%" (said at 0:37:11)
The speaker's estimates of approximately 50% for both side effect and withdrawal/discontinuation rates are roughly consistent with unadjusted incidence figures reported in systematic reviews, but require qualification regarding placebo-subtracted rates and symptom severity.
For antidepressant withdrawal/discontinuation symptoms, systematic reviews and meta-analyses report overall unadjusted incidence rates between 31% and 56%. Specifically, a 2025 meta-analysis found a pooled withdrawal incidence of 42.9% overall and 45.6% for SSRIs, while a 2019 review reported a weighted average incidence of 56%. However, when accounting for placebo responses (nocebo effects and non-specific symptoms), a 2024 meta-analysis estimated that the net drug-attributable incidence of discontinuation symptoms is approximately 15%.
For side effects, a 2023 network meta-analysis of SSRIs and SNRIs found that 80.2% of patients in medication groups reported at least one adverse event (compared to 71.2% in placebo groups). Thus, while crude incidence rates in clinical studies align with ~50% estimates, clinical interpretation requires distinguishing total reported symptom rates from net drug-attributable effects.
- supports: A systematic review into the incidence, severity and duration of antidepressant withdrawal… (Addictive behaviors 2019) · cited 394x in the literature
"Withdrawal incidence rates from 14 studies ranged from 27% to 86% with a weighted average of 56%." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Incidence of adverse events and comparative tolerability of selective serotonin reuptake i… (Psychological medicine 2023) · cited 28x in the literature
"Participants in medication groups presented higher rates of adverse events (80.22%, 95% CI 76.13-83.76) when compared to placebo groups (71.21%, 67.00-75.09)." (abstract, results, passage verified)
pubmedfull study (doi) - context: Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysi… (The lancet. Psychiatry 2024) · cited 96x in the literature
"Incidence of at least one antidepressant discontinuation symptom was 0·31 (95% CI 0·27-0·35) in 62 study groups after discontinuation of antidepressants, and 0·17 (0·14-0·21) in 22 study groups after discontinuation of placebo... Considering non-specific effects, as evidenced in placebo groups, the incidence of antidepressant discontinuation symptoms is approximately 15%" (abstract, results and conclusions, passage verified)
pubmedfull study (doi) - supports: Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and syst… (Molecular psychiatry 2025) · cited 32x in the literature
"The pooled incidence of AWS from all available studies was 42.9%, from 11 RCTs was 44.4%... The incidence in selective serotonin-norepinephrine reuptake inhibitors was the lowest (29.7%), followed by selective serotonin reuptake inhibitors (45.6%) and tricyclic antidepressants (59.7%), without significant differences (p = 0.221)." (abstract, results)
pubmedfull study (doi)
Long-term use of SSRIs and SNRIs for depression is only slightly better in terms of outcomes compared to placebo.
"long-term use of these medications is only slightly better in terms of the outcomes than placebo when— HOST: In the context of depression. GUEST1: In the context of depression." (said at 0:37:16)
The claim that long-term use of SSRIs and SNRIs for depression is only slightly better than placebo is contradicted by extensive meta-analytic evidence from randomized controlled maintenance and discontinuation trials. Systematic reviews demonstrate that long-term maintenance therapy with second-generation antidepressants provides a substantial reduction in depression relapse compared to placebo, roughly halving the risk (relapse rates of approximately 20% on medication versus 40% on placebo over long-term follow-up) with a number needed to treat (NNT) of 5.
mTOR activation is the primary mechanistic pathway responsible for skeletal muscle hypertrophy from resistance training.
"it seems like the major mechanism behind the growth of skeletal muscle through resistance training is mTOR activation." (said at 0:40:20)
Extensive molecular exercise physiology literature confirms that mechanistic target of rapamycin complex 1 (mTORC1) signaling is the principal pathway driving the elevation in muscle protein synthesis and downstream skeletal muscle hypertrophy induced by resistance exercise.
- supports: [Research progress on molecular mechanism of resistance training-induced skeletal muscle h… (Sheng li xue bao : [Acta physiologica Sinica] 2025) · cited 1x in the literature
"Resistance training promotes protein synthesis and hypertrophy, enhancing strength of skeletal muscle through the activation of the mammalian target of rapamycin (mTOR) and the subsequent increases of ribosome biogenesis and translation capacity. Recent studies indicate that resistance training has positive effects on physical fitness and illness treatment, yet the mechanisms underlying hypertrophic adaptation remain insufficiently understood. Human studies focused on the correlation between mTOR signals and hypertrophy-related protein production, while animal research demonstrated that mTOR complex 1 (mTORC1) is the main regulator of resistance training induced-hypertrophy." (abstract, background and conclusions, passage verified)
pubmedfull study (doi) - supports: The Role of Mammalian Target of Rapamycin (mTOR) and Adenosine Monophosphate-Activated Pro… (Cureus 2025) · cited 2x in the literature
"Skeletal muscle functions as a dynamic metabolic organ, and its maintenance depends on the delicate equilibrium between mammalian target of rapamycin (mTOR), which drives anabolic processes, such as protein synthesis and hypertrophy, and adenosine monophosphate-activated protein kinase (AMPK), which promotes catabolic renewal through mitochondrial biogenesis, autophagy, and energy conservation." (abstract, background, passage verified)
pubmedfull study (doi)
Leucine activates mTOR more strongly than other amino acids.
"Research, for example, suggests that leucine activates mTOR more strongly than other amino acids and therefore may lead to more anabolic benefit." (said at 0:40:51)
Published comparative research confirms that leucine activates the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway more potently than other amino acids. Systematic analysis in skeletal muscle cell models shows that leucine uniquely increases mTOR and 4E-BP1 phosphorylation and induces significantly greater downstream p70S6K1 activation than other essential amino acids. Human clinical trials similarly demonstrate that leucine-enriched nutrients rapidly and potently activate muscle mTOR signaling and stimulate muscle protein synthesis.
A 2024 meta-analysis found that whey protein supplementation improves skeletal muscle mass in individuals with sarcopenia compared to placebo.
"so there was a 2024 meta-analysis, they looked at sarcopenia, and they found that whey protein was linked to improvements in skeletal muscle mass, suggesting here that protein supplementation compared to a placebo does actually benefit people who have overt muscle loss in the case of sarcopenia." (said at 0:41:57)
A 2024 systematic review and meta-analysis of 10 randomized controlled trials (1,154 participants) evaluated whey protein supplementation with or without resistance training in older adults diagnosed with sarcopenia. Compared to isocaloric placebo or routine consultation, whey protein supplementation significantly increased appendicular skeletal muscle mass index (SMD: 0.47, 95% CI: 0.23 to 0.71) and appendicular skeletal muscle mass (SMD: 0.28, 95% CI: 0.11 to 0.45), alongside improvements in gait speed.
- supports: Improving sarcopenia in older adults: a systematic review and meta-analysis of randomized … (The journal of nutrition, health & aging 2024) · cited 55x in the literature
"In WP group versus (vs.) Isocaloric placebo (PLA)/Routine consultation (RC) group, WP significantly increased the appendicular skeletal muscle mass index (SMD: 0.47, 95%CI: 0.23, 0.71), appendicular skeletal muscle mass (SMD: 0.28, 95%CI: 0.11, 0.45) and gait speed (SMD: 1.13, 95%CI: 0.82, 1.44) in older patients with sarcopenia." (abstract, results, passage verified)
pubmedfull study (doi)
Protein isolate supplementation combined with resistance training yields superior muscle outcomes compared to resistance training alone.
"And then we have data suggesting that protein consumption, meaning a protein isolate, whey or otherwise, is better with resistance training than just resistance training alone." (said at 0:42:13)
A systematic review and meta-analysis of 49 randomized controlled trials (1,863 participants) found that dietary protein supplementation (such as whey or other protein sources) combined with resistance exercise training significantly enhanced gains in fat-free mass, muscle fiber cross-sectional area, and one-repetition-maximum strength compared to resistance training without protein supplementation.
Exercise alone without dietary modification does not result in sustainable weight loss.
"exercise by itself doesn't lead to sustainable weight loss, but when you do it in conjunction with dietary change, it does." (said at 0:42:14)
Systematic reviews and meta-analyses of randomized controlled trials demonstrate that physical activity alone yields minimal long-term weight loss compared to combined dietary modification and exercise interventions. Interventions combining dietary restriction with exercise achieve significantly greater sustained weight loss at 12 to 18 months than physical activity alone.
Multiple consecutive meta-analyses show that specific protein timing and intake protocols do not significantly affect muscle strength gains.
"But there is additional data suggesting that protein guidelines, meaning the exact amount of protein you should take, when you should take that protein in terms of building muscle strength, doesn't matter that much. And that's been shown actually in several consecutive meta-analyses, which is really interesting." (said at 0:42:21)
Multiple systematic reviews and meta-analyses of randomized controlled trials have investigated the effect of peri-workout protein timing on muscle strength and hypertrophy. These analyses consistently find that specific timing of protein ingestion (e.g., within a narrow window before or immediately after resistance training) does not significantly impact muscle strength gains or hypertrophy when total daily protein intake is controlled for.
- supports: The effect of protein timing on muscle strength and hypertrophy: a meta-analysis. (Journal of the International Society of Sports Nutrition 2013) · cited 197x in the literature
"In the full meta-regression model controlling for all covariates, however, no significant differences were found between treatment and control for strength or hypertrophy... These results refute the commonly held belief that the timing of protein intake in and around a training session is critical to muscular adaptations and indicate that consuming adequate protein in combination with resistance exercise is the key factor for maximizing muscle protein accretion." (abstract, results and conclusions)
pubmedfull study (doi) - supports: The Role of Protein Intake and its Timing on Body Composition and Muscle Function in Healt… (The Journal of nutrition 2020) · cited 85x in the literature
"Subgroup analyses showed no beneficial effect of a specific timing of protein intake on LBM, handgrip strength, and leg press strength. Overall, the results support the positive impact of protein supplementation on LBM of adults and older adults, independently of intake timing." (abstract, results and conclusions, passage verified)
pubmedfull study (doi) - supports: Does Protein Ingestion Timing Affect Exercise-Induced Adaptations? A Systematic Review wit… (Nutrients 2025) · cited 2x in the literature
"Recently, several meta-analyses have concluded that protein supplementation timing does not alter muscle strength and mass gains... For the chest press exercise, there was no effect of protein timing on repeated maximum (RM)... subgroup analysis did not reveal a significant effect difference (p = 0.07) for leg press and chest press." (abstract, background and results)
pubmedfull study (doi)
The minimum recommended dietary allowance for protein for the general population is approximately 0.8 grams per kilogram of body weight (or 0.36 grams per pound).
"generally, what I would say is you're shooting for about 0.8 grams of protein per kilogram at a minimum for the average— HOST: Ideal body weight. GUEST1: Ideal body weight, right. Correct. And so that translates to about 0.36 grams per pound." (said at 0:43:16)
The speaker's statement accurately reflects standard dietary reference intake guidelines. The established Recommended Dietary Allowance (RDA) for protein in healthy adults is 0.8 grams per kilogram of body weight per day (which converts to approximately 0.36 grams per pound of body weight per day).
Plant-based protein sources generally contain lower amounts of bioavailable leucine than animal-based sources.
"It is true that when we look at certain amino acids, for example leucine, which is important, as I mentioned, in terms of activating mTOR, but also in terms of just being a pro-anabolic amino acid, that there are lower levels of bioavailable leucine typically in plant-based sources." (said at 0:43:23)
The speaker claimed that plant-based protein sources generally contain lower amounts of bioavailable leucine compared to animal-based sources. Literature reviews and comparative studies confirm that plant-based proteins typically possess lower essential amino acid contents—particularly lower leucine content—and lower digestibility/bioavailability compared to animal-derived proteins, resulting in lower postprandial blood leucine spikes and reduced anabolic potential unless fortified or consumed in larger quantities.
- supports: Protein content and amino acid composition of commercially available plant-based protein i… (Amino acids 2018) · cited 1146x in the literature
"Lower EAA contents and specific lack of sufficient leucine, lysine, and/or methionine may be responsible for the lower anabolic capacity of plant-based compared with animal-based proteins." (abstract, results, passage verified)
pubmedfull study (doi) - supports: The Role of the Anabolic Properties of Plant- versus Animal-Based Protein Sources in Suppo… (Nutrients 2019) · cited 464x in the literature
"plant-based proteins have less of an anabolic effect than animal proteins due to their lower digestibility, lower essential amino acid content (especially leucine), and deficiency in other essential amino acids" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Dampened Muscle mTORC1 Response Following Ingestion of High-Quality Plant-Based Protein an… (Nutrients 2021) · cited 15x in the literature
"Ingestion of plant-based proteins induced a lower rise in blood leucine compared to whey, which coincided with a dampened mTORC1 activation, both acutely and 150 min after administration." (abstract, results, passage verified)
pubmedfull study (doi)
For adults over age 65 or individuals actively trying to build muscle, the substantiated target protein range is between 1.2 and 2.0 to 2.2 grams per kilogram of body weight per day.
"for those people, and it may be most people who are listening to this podcast who are either over age 65 or who are actively trying to build more healthy muscle, I think going higher makes sense. And so the range that I've seen most substantiated here is between 1.2 to 2 grams per kilogram, up to maybe 2.2 grams per kilogram." (said at 0:43:33)
The stated protein range of 1.2 to 2.0–2.2 g/kg/day is well-supported by expert consensus statements and meta-analyses of randomized controlled trials for older adults and individuals undergoing resistance training. For older adults (over age 65), the PROT-AGE study group recommends 1.0 to 1.2 g/kg/day for maintaining lean mass, and ≥1.2 to 2.0 g/kg/day for active older adults or those with chronic conditions. For individuals aiming to build muscle through resistance exercise, a systematic review and meta-analysis of 49 RCTs (Morton et al., 2018) identified a breakpoint of 1.62 g/kg/day (with the upper 95% confidence interval extending to ~2.2 g/kg/day) beyond which additional protein did not significantly augment gains in fat-free mass.
Approximately 6% of the body's total creatine stores are located in the brain.
"and creatine is primarily stored in your muscles. There's a little bit, around 6%, stored in your brain." (said at 0:45:55)
The speaker correctly identifies that creatine is predominantly stored in skeletal muscle with a small fraction in the brain. However, established physiological literature indicates that approximately 95% of total body creatine is stored in skeletal muscle, while the remaining ~5% is distributed across several tissues with high metabolic demand, including the brain, heart, kidneys, and testes. Therefore, the brain alone does not store ~6% of total body creatine, but rather represents a fraction of the non-muscular ~5% pool.
Creatine supplementation in healthy adults correlates with improvements in cognitive function and brain health outcomes.
"research shows that when you supplement with creatine, there are potential benefits to be gained not only in muscle health, which is the way that everyone's used it for decades, but now in cognition in healthy adults. And I just I don't see any sort of research like this for other supplements, which is take a healthy adult and give them creatine for, you know, a couple of weeks, couple of months, that there are correlations with better brain health outcomes." (said at 0:46:10)
Systematic reviews and meta-analyses of randomized controlled trials demonstrate that creatine supplementation confers modest benefits on cognitive performance in healthy adults, particularly in memory tasks, processing speed, and attention. Benefits on memory appear to be most pronounced in older adults (aged 66–76 years) and under conditions of cognitive or metabolic stress, while overall executive function and general cognitive scores show more variable outcomes.
- supports: Effects of creatine supplementation on memory in healthy individuals: a systematic review … (Nutrition reviews 2023) · cited 69x in the literature
"Overall, creatine supplementation improved measures of memory compared with placebo (standard mean difference [SMD] = 0.29, 95%CI, 0.04-0.53; I2 = 66%; P = 0.02). Subgroup analyses revealed a significant improvement in memory in older adults (66-76 years) (SMD = 0.88; 95%CI, 0.22-1.55; I2 = 83%; P = 0.009) compared with their younger counterparts (11-31 years) (SMD = 0.03; 95%CI, -0.14 to 0.20; I2 = 0%; P = 0.72)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: The effects of creatine supplementation on cognitive function in adults: a systematic revi… (Frontiers in nutrition 2024) · cited 40x in the literature
"Creatine supplementation showed significant positive effects on memory (SMD = 0.31, 95% CI: 0.18-0.44, Hedges's g = 0.3003, 95% CI: 0.1778-0.4228) and attention time (SMD = -0.31, 95% CI: -0.58 to -0.03, Hedges's g = -0.3004, 95% CI: -0.5719 to -0.0289), as well as significantly improving processing speed time (SMD = -0.51, 95% CI: -1.01 to -0.01, Hedges's g = -0.4916, 95% CI: -0.7852 to -0.1980)." (abstract, results, passage verified)
pubmedfull study (doi)
Caloric restriction extends lifespan in animals compared to ad libitum feeding.
"animals on calorie-restricted diets are the longest-lived people or animals, I should say. So you don't really see, you know, the super bulky, muscular rats and mice being the ones that survive." (said at 0:47:06)
Extensive experimental animal research and meta-analyses demonstrate that dietary and caloric restriction reliably extends median and maximum lifespan in laboratory rodents and other model organisms compared to ad libitum feeding. Meta-analyses of rodent survival curves confirm that dietary restriction significantly reduces the rate of aging and prolongs survival in both rats (increasing median lifespan typically by 14% to 45%) and mice (typically by 4% to 27%), although the magnitude of the effect varies by sex, strain, and genetic background.
HMB (beta-hydroxy beta-methylbutyrate) is a breakdown metabolite of leucine that has been shown in studies to improve muscle strength when taken as a supplement.
"beta-hydroxy beta-methylbutyrate, HMB, this is an interesting molecule. It's a breakdown product of leucine, and it has been studied to be beneficial in terms of benefiting people's muscle strength when it's consumed in supplemental form." (said at 0:47:25)
Beta-hydroxy-beta-methylbutyrate (HMB) is an endogenous metabolite of the essential branched-chain amino acid leucine. Numerous randomized controlled trials and meta-analyses have investigated HMB supplementation for muscle mass and strength. While meta-analyses in trained young athletes show minimal or no significant benefit on strength, meta-analyses in older adults and previously untrained individuals demonstrate small to moderate significant improvements in muscle strength and preservation of lean mass.
Omega-3 fatty acid supplementation (EPA and DHA) improves overall muscle strength, specifically lower extremity strength.
"that omega-3 supplementation—specifically, we're talking about EPA, or eicosapentaenoic acid, and DHA, or docosahexaenoic acid—may benefit overall strength and specifically may benefit lower extremity strength, which is so important." (said at 0:48:04)
Systematic reviews and meta-analyses of randomized controlled trials support the claim that long-chain omega-3 fatty acid (EPA and DHA) supplementation can improve muscle strength, particularly lower-body strength and related functional outcomes in older adults. A 2022 meta-analysis of 16 studies in older adults reported significant improvements in lower-body strength (SMD 0.54, 95% CI: 0.33 to 0.75) and sit-to-stand performance, without significant gains in upper-body strength. Similarly, a 2023 meta-analysis encompassing young and older adults found a small overall positive effect of omega-3 supplementation on total muscle strength.
- supports: Effects of Omega-3 Supplementation Alone and Combined with Resistance Exercise on Skeletal… (Nutrients 2022) · cited 76x in the literature
"Benefits were observed for lower body strength (SMD 0.54 [0.33, 0.75]), timed-up-and-go (MD 0.29 [0.23, 0.35]s), and 30-s sit-to-stand performance (MD 1.93 [1.59, 2.26] repetitions) but not walking performance (SMD -0.01 [-0.10, 0.07]) or upper body strength (SMD 0.05 [-0.04, 0.13]). Supplementing with ω-3 fatty acids may improve the lower-body strength and functionality in older adults." (abstract, results, passage verified)
pubmedfull study (doi) - supports: The Influence of n-3PUFA Supplementation on Muscle Strength, Mass, and Function: A Systema… (Advances in nutrition (Bethesda, Md.) 2023) · cited 26x in the literature
"n-3PUFA supplementation had no significant effect on muscle mass (standard mean difference [SMD] = 0.07 [95% CI: -0.02, 0.17], P = 0.11) and muscle function (SMD = 0.03 [95% CI: -0.09, 0.15], P = 0.58), but it showed a very small albeit significant positive effect on muscle strength (SMD = 0.12 [95% CI: 0.006, 0.24], P = 0.04) in participants when compared with placebo." (abstract, results, passage verified)
pubmedfull study (doi)
Consuming large amounts of branched-chain amino acids over extended periods can contribute to metabolic dysfunction.
"some of these branched-chain amino acids can actually lead to metabolic dysfunction when consumed in large amounts over long periods of time." (said at 0:50:44)
No published record matching the claim that consuming large amounts of branched-chain amino acids over extended periods contributes to metabolic dysfunction was located; this does not prove the claim false.
Estrogen acts as an immunomodulator and directly modulates neuroplasticity.
"estrogen is an immunomodulator. Estrogen modulates neuroplasticity." (said at 1:00:50)
Extensive preclinical and translational evidence confirms that estrogen acts as an immunomodulator—influencing cytokine signaling, microglial activation, and neuroinflammatory pathways—and directly regulates neuroplasticity, including dendritic spine density, synapse formation, and long-term potentiation in regions such as the hippocampus.
The majority of human skeletal muscle mass and the largest skeletal muscles in the body are located in the legs.
"the majority of your skeletal muscle mass: the biggest skeletal muscles in your body are in your legs." (said at 1:05:18)
No published record matching the claim regarding the exact proportion of total body skeletal muscle mass located in the lower limbs versus other anatomical regions was located; this does not prove the claim false.
Activating leg muscle groups through exercises like squats, deadlifts, leg presses, and lunges helps clear glucose from the bloodstream, regulate immune function, and support brain health.
"Lunges, especially weighted lunges, these are great ways to get those muscles activated to pull the glucose out of your bloodstream, to regulate your immune system, and promote healthier brain function." (said at 1:05:38)
Activating major skeletal muscle groups through resistance exercises such as lunges promotes glucose clearance from the bloodstream, modulates immune function, and supports brain health. During muscle contraction, glucose transporter type 4 (GLUT4) translocates to the cell membrane via insulin-independent and insulin-dependent pathways (such as AMPK activation), facilitating direct glucose uptake. Furthermore, contracting skeletal muscle functions as an endocrine organ, releasing myokines and anti-inflammatory signaling molecules that regulate systemic immune homeostasis, reduce chronic low-grade inflammation, and enhance neurotrophic support (such as brain-derived neurotrophic factor, BDNF) for brain health.
- supports: Update on the effects of physical activity on insulin sensitivity in humans. (BMJ open sport & exercise medicine 2016) · cited 633x in the literature
"During exercise, muscle contraction stimulated improvements in SI are associated with increases in AMPK activity, which deactivates TCB1D1, promoting GLUT4 translocation to the cell membrane and thereby increasing glucose uptake." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Exercise orchestrates systemic metabolic and neuroimmune homeostasis via the brain-muscle-… (European journal of medical research 2025) · cited 51x in the literature
"Mechanistically, exercise enhances mitochondrial biogenesis and oxidative capacity in skeletal muscle via AMPK/PGC-1α signaling, restoring fatty acid oxidation and glucose metabolism while producing myokines (e.g., BDNF and IL-6) that promote neuronal survival and synaptic plasticity." (abstract, results, passage verified)
pubmedfull study (doi)
Fact-checked episodes
Publications